Brief: Kintara Therapeutics Provides Update On Corporate Developments And REM-001 Clinical Study
11/09/2024 16:06
Sept 11 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* KINTARA THERAPEUTICS PROVIDES UPDATE ON CORPORATE
DEVELOPMENTS
AND REM-001 CLINICAL STUDY
* KINTARA THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY
ISSUES
IDENTIFIED IN REM-001 STUDY
* KINTARA THERAPEUTICS INC - MAY SEEK BANKRUPTCY PROTECTION
WITHOUT TUHURA MERGER
Source text for Eikon: ID:nPnyjK2Ra
Further company coverage: KTRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.